

2nd Quarter report for 2016 Date: **8/18/16**

Percentage change in Sales from year ago quarter 17.8%

Percentage change in Earnings per Share from year ago quarter 18.1%
(from top left box on p. 1 of SSG)

Is company meeting our target sales & earnings estimates at bottom of p. 1 of SSG? Yes

Pre-tax Profit on sales trend? (up, even, down) UP

Return on equity trends? (up, even, down) UP

Debt? (up, even, down) UP

Current PE is 19.2. (Section 3 SSG)

Where does it fall in my estimated High/low range of PE's? Middle

Signature PE = NMF

Club cost basis for this stock is 32.83. Current price is 66.77
(from latest valuation)

Has stock met S&P's 12-month target price from a year ago? No \$76.00

Current fair value: Morningstar: 73. S&P: 123.80

My SSG Total Return is 10.9 Projected Average Return is 6.7

What will drive future growth? Sales of Humira are having greater penetration into the emerging markets. Recently purchased new company "Stemcentrx, a development stage oncology firm with 5 compounds in trials for rx. of small cell lung cancer and three types of blood cancers.

Additional comments:

Recommend: Buy More _____, Hold XXX, Challenge with a better investment _____, Sell _____.